Tony van Bijleveld, General Manager for Patheon/DPX, & Former General Manager Europe for Alliance Boots Walgreens, Appointed ...
September 22 2014 - 11:20AM
Business Wire
Vantage Health Inc. (OTCQB:VNTH) ("Vantage Health" or the
"Company") today announced the appointment of Tony van Bijleveld as
an independent member of the Board of Directors of Vantage Health,
Inc.
Mr. van Bijleveld is currently General Manager with leading drug
manufacturer Patheon/DPX. Patheon is a leading global provider of
contract drug development and manufacturing services. Their
integrated network consists of seven development centers of
excellence and thirteen manufacturing facilities across North
America, Asia and Europe. Patheon provides pharmaceutical and
biotechnology companies with direct access to the expertise,
quality and full range of solid and sterile dosage forms to bring
drug candidates from preclinical stages through production, and
launch products anywhere in the world.
Up until this past spring, Mr. van Bijleveld was the General
Manager of Europe for Alliance Boots which is 45% owned by
Walgreens. In this capacity he was responsible for European country
operations and logistics. Alliance Boots, with a presence in more
than 25 countries and over 108,000 employees is a leading
international, pharmacy-led health and beauty group delivering a
range of products and services to customers. Their focus is on
pharmacy-led retailing and pharmaceutical wholesaling and
distribution. Alliance Boots operate more than 3,150 health &
beauty retail stores, of which just over 3,050 have a pharmacy.
Mr. van Bijleveld has been instrumental in the development of
top-performing global businesses in diagnostics, pharmaceuticals
and biotechnology industries in over 30 countries, reflecting his
experience in general management, marketing and sales management,
acquisitions, operational excellence, and licensing and business
development.
Over the past 30 years he has served in a variety of senior
executive capacities in the pharmaceutical and biotech industry
including: Managing Director of United Drug PLC, President/General
Manager Russia for Schering Plough/MSD, SVP of Organon Biosciences,
and Managing Director of KCL Foundation Labs. A native Australian,
Mr. van Bijleveld has earned advanced degrees in Pharmacology,
Biochemistry, Engineering and an MBA, from colleges in Australia,
Holland and Candean.
More news will be forthcoming this week as the Company expands
and reconstitutes its Board.
About Vantage Health
Inc.
Vantage Health Inc. - a mobile health technology company - is
developing personalized and point-of-care screening using Apps
based upon chemical sensing residing within a small device attached
to a smartphone. With its foundations in advanced nanotechnology,
the company’s first product, the Vantage Health Sensor, which is in
development, is the convergence of nano-electronics,
bio-informatics, and wireless technology to create the next
generation mobile health application. The first mobile App is
expected to be for lung cancer screening with additional mobile
healthcare Apps in the planning stages. The company has offices in
Redwood City, CA and New York. For more information, please visit
http://www.vantagehealthinc.com
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include, among other
things statements with respect to our objectives and strategies to
achieve those objectives, as well as statements with respect to our
beliefs, plans, expectations, anticipations, estimates or
intentions. Such forward-looking statements may also include
statements, among other things, concerning the efficacy, safety and
intended utilization of Vantage’s product candidates, the conduct
and results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include, among others, the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Vantage may not obtain approval to market its product candidates,
or outside financing may not be available to meet capital
requirements. These forward-looking statements are based on our
current expectations. We caution that all forward-looking
information is inherently uncertain and actual results may differ
materially from the assumptions, estimates or expectations
reflected or contained in the forward-looking information, and that
actual future performance will be affected by a number of factors,
including economic conditions, technological change, regulatory
change and competitive factors, many of which are beyond our
control. Therefore, future events and results may vary
significantly from what we currently foresee.
For a further list and description of the risks and
uncertainties the Company faces, please refer to the Company’s most
recent Annual Report on Form 10-K and other periodic and other
filings Vantage files with the Securities and Exchange Commission
and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and Vantage assumes
no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
Investors:CSIR Group,
LLCChristine Petraglia, 212-386-7082
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024